The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
14-Nov-16
$748 million
Target:
Peacock Foods
Acquiror:
Greencore Group plc
Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.
14-Nov-16
$NA
Target:
Lion’s Australian Premium Wine Business – Fine Wine Partners
Acquiror:
Accolade Wines
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
17-Jun-16
$310 million
Target:
Dobbies Garden Centres
Acquiror:
Investor group led by Midlothian Capital Partners and Hattington Capital
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital
10-Jun-16
$NA
Target:
Giraffe restaurants
Acquiror:
Boparan Private Office
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan
01-Jun-16
$221 million
Target:
Patties Foods Ltd
Acquiror:
Pacific Equity Partners
Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
21-Apr-15
$NA
Target:
Tate & Lyle plc
Acquiror:
Archer Daniels Midland Company
Advised Tate & Lyle plc, a leading provider of ingredients and solutions to the food, beverage and other industries, on the re-alignment of Eaststarch C.V., its 50:50 corn wet milling joint venture in Europe with Archer Daniels Midland Company
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
27-Mar-15
$1.4 billion
Target:
AA plc
Advised AA plc, the UK’s leading roadside assistance provider, on the refinancing of its high yield bond and PIK instrument
06-Mar-15
$NA
Target:
Kerry Pinnacle
Acquiror:
Pacific Equity Partners
Advised Kerry Group plc, a global leader in food ingredients and flavor technologies, on the sale of its Australian subsidiary Kerry Pinnacle, an integrated manufacturer and distributor of bakery ingredients and prepared bakery products, to Pacific Equity Partners
03-Mar-15
$66 million
Target:
The Warehouse Group Limited
Advised Woolworths Limited, Australia’s largest supermarket operator, on strategic options for the divestment of its 8.8% holding in The Warehouse Group, New Zealand’s largest general merchandise retailer
02-Mar-15
$107 million
Target:
Lion's Everyday Cheese Business
Acquiror:
Warrnambool Cheese & Butter
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Everyday Cheese business to Warrnambool Cheese & Butter, a listed Australian dairy company controlled by the Canadian dairy player Saputo
01-Oct-14
$NA
Target:
Modern Star Pty Ltd
Acquiror:
Navis Capital
Advised Modern Star, Australia and New Zealand’s #1 supplier of education resources and educational toys, on the sale of 90% of its shares to Navis Capital, a leading private equity group focused on investments in South and Southeast Asia
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
25-Jul-14
$NA
Target:
Stakes in David Jones and Country Road
Acquiror:
Woolworths Holdings
Advised Solomon Lew in reviewing his strategic options in relation to David Jones and Country Road. Mr Lew ultimately sold his 11.8% stake in the tightly held Country Road to Woolworths Holdings. Woolworths Holdings also acquired David Jones, Australia’s premier department store, in which Mr Lew held a 9.9% stake
26-Jun-14
$2.7 billion
Target:
Frank Russell Company
Acquiror:
London Stock Exchange Group plc
Advised LSEG on the proposed acquisition of Frank Russell Company, the number one provider of benchmarks to US-focused equity funds and a leading provider of multi-asset class investment solutions, from Northwestern Mutual Life Insurance Company, including acting as Joint Sponsor to LSEG on its $1.6 billion rights issue
06-Jun-14
$7.2 billion
Target:
AA Limited
Advised the management buy-in team on the acquisition by leading institutional investors of AA Limited from Acromas and simultaneous listing on the London Stock Exchange